Search Results - Suzana Vega Harring
- Showing 1 - 2 results of 2
-
1
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies by Sebastian Dziadek, Anton Kraxner, Wei‐Yi Cheng, Tai-Hsien Ou Yang, Mike Flores, Noah Theiss, Tsu‐Shuen Tsao, Emilia Andersson, Suzana Vega Harring, Ann‐Marie Bröske, Maurizio Ceppi, Volker Teichgräber, Jehad Charo
Published 2024Artigo -
2
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis by Peter Brünker, Katharina Wartha, Thomas Friess, Sandra Grau-Richards, Inja Waldhauer, Claudia Ferrara, Barbara Weiser, Meher Majety, Valeria Runza, Huifeng Niu, Kathryn Packman, Ningping Feng, Sherif Daouti, Ralf J. Hosse, Ekkehard Mössner, Thomas G. Weber, Frank Herting, Werner Scheuer, Hadassah Sade, Cuiying Shao, Bin Liu, Peng Wang, Gary Xu, Suzana Vega-Harring, Christian Klein, Klaus Bosslet, Pablo Umaña
Published 2016Artigo
Search Tools:
Related Subjects
Biochemistry
Cancer
Cancer research
Fibroblast activation protein, alpha
Internal medicine
Medicine
Antibody
Apoptosis
Atezolizumab
Avidity
Biology
Biomarker
Cancer cell
Chemistry
Clinical significance
Immunohistochemistry
Immunology
Immunotherapy
Lung cancer
Mesothelin
Nivolumab
Oncology
Targeted therapy